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Purpose or Objective: The fear of radiotherapy-induced 
urinary incontinence (URINC) often contraindicates post-
prostatectomy RT (POPRT), despite the lack of accurate data 
about its real incidence and severity. The purpose of this 
analysis was to analyze clinico-dosimetric factors predicting 
severe, self-reported URINC 1 and 2 years after POPRT. 
 
Material and Methods: In 2012 a longitudinal, observational 
study aimed at assessing URINC from POPRT including 
prophylactic whole-pelvis irradiation (WPRT) was activated at 
our Institute. For the evaluation of urinary toxicity, 2 
validated questionnaires, IPSS and ICIQ-SF, are to be filled-in 
by pts at baseline, at RT mid-point and end, at 3 and 6 
months after RT conclusion, and every 6 months thereafter. 
This analysis pertains to the first 101 pts correctly filling the 
questionnaires at baseline and at 12 months (60 also at 2 
years). Fifty-four and 47 pts were treated with adjuvant 
(ADV) and salvage (SALV) intent after a median of 4 and 38 
months, respectively, from radical prostatectomy (RP), with 
either conventional (n=42) or moderately hypofractionated 
(n=59) regimens, at a median 2-Gy equivalent dose (EQD2) to 
the prostatic bed of 70 and 74 Gy in ADV and SALV cohort, 
respectively, and a median EQD2 dose of WPRT of 50 Gy. 
 
Results: The mean baseline ICIQ scores were 7.8 and 4.8 in 
ADV and SALV cohorts, respectively (p=0.009). The 
corresponding values at 1 and 2 years were 7.4 vs 7.3 and 8.5 
vs 7.9, respectively. Severe URINC (³ 13 points) was recorded 
in 23% and 19% at 1 year, and in 37% and 21% of pts treated 
with ADV and SALV intent, respectively (p≤0.20). The 75th 
quartiles of ICIQ at 12 (ICIQ12) and 24 (ICIQ24) months (12 
and 13 points, respectively), were set as end-points for 
regression logistic analysis. Several clinico-dosimetric factors, 
including age, diabetes, hypertension, pT and pN stage, # of 
removed LNs, RT intent, time from RP to RT, fractionation, 
EQD2, adjuvant androgen deprivation (AAD), IQIQ and IPSS 
baseline values were analyzed. Variables with a p-value <0.20 
at univariable analysis were entered into a backward 
stepwise multivariable model indicating baseline ICIQ and 
nocturia (IPSS item #7) and AAD as predictors of ICIQ12 (AUC 
94%), while baseline ICIQ and EQD2 predicted ICIQ24 (AUC 
89%). 
 
 
 
Conclusion: The risk of long-term severe URINC 1 and 2 years 
after POPRT is strongly modulated by baseline URINC, and by 
AAD and higher EQD2, respectively (Figure 1).  
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Purpose or Objective: In the present study, conventionally 
fractionationed volumetric arc therapy (VMAT) and 
hypofractionated stereotactic body radiotherapy (SBRT) 
modalities were aimed to compare in terms of side effects 
and quality of life (QOL) in patients with localized prostate 
cancer.  
 
Material and Methods: Patients who admitted to I.U. 
Institute of Oncology with a diagnosis of localized prostate 
cancer during the period from March 2010 to December 2013 
were included into the study. Patients received radical RT 
with dose schedules of either 33.5 Gy/5 fr for SBRT or 75.6 
Gy/35 fr for VMAT. Acute and late side effects of treatment 
were evaluated according to CTCAE version 4. IPSS and 
EORTC QOL-PR25 forms were used to assess QOL at baseline, 
end of treatment and during follow-up. 
 
Results: Of the 48 patients (28 SBRT, 20 VMAT) who were 
included into the study, 40 (20 SBRT, 20 VMAT) were 
evaluated for their QOL status. All demographic and 
pathological features including median age of the patients, 
clinical manifestations, and the risk groups were found to be 
similar between treatment groups. PSA control rates were 
%100 in both arms during the follow up with a median of 23 
months. PSA nadir values were detected to be 0.5 ng/dl in 
both arms. PSA bounce was observed in 43% and 50% of 
patients in SBRT and VMAT arms, respectively. The 
magnitude of PSA bounce value was significantly higher in 
SBRT arm compared with VMAT (0.8 ng/dl vs. 0.1 ng/dl, 
p=0.01). PSA decline rate in VMAT arm was found to be 
significantly higher than in SBRT arm (p = 0.028). Grade 3 
rectal toxicity was not observed in any of the treatment 
arms. Although Grade 3 urinary side effects were not seen in 
patients treated with VMAT technique, 3 patients (10.7%) in 
SBRT arm with a history of TURP before RT experienced 
Grade 3 urinary toxicity. No significant difference was 
observed between the two arms concerning sexual activity 
functioning and sexual functioning scores whereas the scores 
at 10.5 and 13.5 months were found to be significantly 
decrased compared with baseline in both treatment arms. 
SBRT and VMAT arms did not differ significantly regarding 
urinary, incontinence, bowel symptom scores and IPSS 
obstruction scores. The magnitude of increase in IPSS scores 
at the end of the treatment compared with baseline were 
detected to be significantly higher in VMAT arm than SBRT 
arm (p=0.046). The decrease in hormonal symptom scores at 
4.5, 10.5 and 13.5 months compared with baseline was 
detected to be significantly higher in VMAT arm than SBRT 
arm (p=0.007, p=0.027, and p=0.021, respectively). 
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Conclusion: Both SBRT and VMAT treatments were highly 
successful in terms of PSA control. QOL assessment were 
found to be mostly similar between treatment modalities. 
Grade 3 urinary toxicities might be eliminated with careful 
patient selection for SBRT technique 
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Purpose or Objective: The aim of this work is to develop an 
algorithm to predict recurrence in prostate cancer patients 
treated with radical radiotherapy, getting up to a prognostic 
power higher than traditional D'Amico risk classification.  
 
Material and Methods: 2493 men belonging to the EUREKA-2 
retrospective multi-centric database on prostate cancer and 
treated with external-beam radiotherapy (3D-CRT and or 
IMRT) as primary treatment comprised the study population. 
A Cox regression time to PSA failure analysis was performed 
in univariate and multivariate settings, evaluating the 
predictive ability of age, pre-treatment PSA, clinical-
radiological staging, Gleason score and percentage of positive 
cores at biopsy (%PC). The accuracy of this model was 
checked with bootstrapping statistics. Subgroups for all the 
variables' combinations were combined to classify patients 
into five different "Candiolo" risk-classes for biochemical 
Progression Free Survival (bPFS); thereafter, they were also 
applied to clinical PFS (cPFS), systemic PFS (sPFS) and 
Prostate Cancer Specific Survival (PCSS), and compared to 
D'Amico risk grouping performances.  
 
Results: the Candiolo classifier splits patients in 5 risk-groups 
with the following 10-years bPFS, cPFS, sPFS and PCSS: for 
very-low-risk 90%, 94%, 100% and 100%; for low-risk 74%, 88%, 
94% and 98%; for intermediate-risk 60%, 82%, 91% and 92%; 
for high-risk 43%, 55%, 80% and 89% and for very-high-risk 
14%, 38%, 56% and 70%. Our classifier outperforms D'Amico 
risk classes for all the end-points evaluated, with 
concordance indexes of 71.5%, 75.5%, 80% and 80.5% versus 
63%, 65.5%, 69.5% and 69%, respectively.  
 
Conclusion: Our classification tool, combining five clinical 
and easily available parameters, seems to better stratify 
patients in predicting prostate cancer recurrence after 
radiotherapy compared to the traditional D'Amico risk 
classes. This classifier must be validate by another prostate 
cancer series.  
References: Gabriele D et al: Beyond D'Amico risk classes for 
predicting recurrence after external beam radiotherapy for 
prostate cancer: the Candiolo classifier. Radiat Oncol 2015, 
in press 
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Purpose or Objective: To test the hypothesis that 
rectal/bladder preparation is associated with an increase in 
Cancer Specific Overall Survival (CSOS), in Clinical Disease 
Free (CDFS) and Biochemical Disease free Survival (BDFS) 
 
Material and Methods: From October 1999 to March 2012, 
1080 prostate cancer patients (PCa) were treated with 
3DCRT. 761 patients (pts) were treated with empty rectum 
and comfortable full bladder while for 319 pts no 
rectal/bladder preparation (NRBP) protocol was adopted. The 
mean age was 69.2±5.6 years. The mean prescribed dose was 
76±2 Gy. The mean followup was 81±39 months. Survival 
analysis was performed by Kaplan Meier method. Comparison 
between groups were made with the log–rank test. A Cox 
proportional hazards model was applied for univariate (UVA) 
and multivariate analysis (MVA). Hazard Ratio (HR) was used 
to measure how rapidly an event occurs. 
 
Results: Pts with rectal/bladder preparation (RBP) have 
significantly lower biochemical and clinical failures rates and 
lower risk of dying of PCa respect to NRBP pts (log-rank 
p<0.0001). At 140 months for RBP and NRPB, the CSOS was 
95% vs 85%, the CDFS was 81% vs 71%, the BDFS was 64% vs 48 
%, respectively. Table 1 shows UVA and MVA results. In MVA, 
for CSOS the Gleason Score (GS) and RBP predicted for death 
from PCa, while for CDSF and BDFS the GS, D’Amico Risk 
Classification, PSA, dose>75 Gy, clinical stage and RBP 
